Dr Ying-Xian Pan – The Holy Grail of Safer Opioids: Targeting Mu Opioid Receptor Splice Variants
Despite their numerous side effects, opioid drugs and morphine-like agents have remained a pillar in the medical management of pain. Most clinically used opioid drugs act through mu opioid receptors. Dr Ying-Xian Pan and his team from the Rutgers New Jersey Medical School, USA, studies the molecular and cellular mechanisms of mu opioid receptors and aim to develop novel strategies and opioid analgesics for better treating pain without side effects associated with traditional opiates. Efforts to find substitutes for traditional opioid drugs are helping address the opiate abuse crisis that affects many countries around the globe.
Identifying Multiple Splice Variants of Mu Opioid Receptor Gene
The actions of clinically used opioid drugs are complicated. Although potent in relieving pain, these drugs produce many side effects and their misuse has led to the global opioid epidemic. Dr Ying-Xian Pan, Professor of Anesthesiology at Rutgers New Jersey Medical School, USA, and his team have long investigated the molecular and cellular mechanisms of mu opioid actions that are mediated through mu opioid receptors. This work is providing the foundations to develop novel opioid analgesics that are devoid of unwanted side effects and the potential for abuse.
One of the main findings from Dr Pan’s laboratory is that the gene encoding mu opioid receptors, known as OPRM1, is able to generate multiple isoforms or variants of the receptor through ‘alternative splicing’, a process that allows a single gene to produce more than one protein. Over the past years, Dr Pan’s laboratory and others have identified over 65 mu opioid receptor variants from the mouse, rat and human OPRM1 gene. These variants can be categorised into three structurally distinct classes.
The first class of the variants have identical full-length seven transmembrane domains (7TM) sequences, a typical G protein coupled receptor structure, except for an alternative intracellular carboxyl terminal sequence. The second class of the variants are called truncated 6TM variants due to the lack of the first TM. The third class of the variants are truncated single TM variants. Single TM variants only contain the first TM.
Importantly, this alternative splicing of the OPRM1 gene is conserved from rodents to humans, meaning that it is evolutionarily important in its functions. To define the molecular mechanisms of various analgesic drugs acting on the mu opioid receptor splice variants, Dr Pan and his team adopt multidisciplinary in vitro and in vivo approaches, including molecular biology, biochemistry, pharmacology, and behavioural studies, as well as gene targeting animal models.
Targeting Truncated 6TM variants
Dr Pan and his collaborators have long been involved in researching the Holy Grail of mu opioid analgesics. In vivo studies using a genetically engineered exon 11 knockout mouse model generated in Dr Pan’s laboratory led to the discovery of the functional importance of the truncated 6TM variants. In 2009, Dr Pan and his team published an article in the prestigious Proceedings of the National Academy of Sciences of the United States of America (PNAS), exploring the role of truncated 6TM variants on the action of heroin, a mu receptor agonist. Disrupting the exon 11 sequence that deleted all 6TM variants in the exon 11 knockout mouse did not affect the pain-relieving action of morphine and methadone. However, it attenuated the pain-relieving action of heroin.
These findings established a role for the exon 11-associated 6TM variants in heroin action and complemented the earlier finding in an exon 1 knockout mouse generated by Dr John Pintar’s laboratory, in which all 7TM variants were lost but all 6TM variants were retained. Heroin analgesia was still active while morphine and methadone analgesia were both completely lost.
Dr Pan and his collaborators, including Drs Pasternak and Majumdar, further extended their studies to the action of novel opioid analgesic drugs targeting the 6TM variants. In these studies, the researchers identified a novel potent opiate analgesic and published the findings in PNAS in 2011. The novel agonist, 3-iodobenzoyl-6β-naltrexamide (IBNtxA) developed by Drs Majumdar and Pasternak, acts through the truncated 6TM variants of the murine mu opioid receptor gene (Oprm1). They observed that the analgesic action of IBNtxA was lost in the exon 11 knockout mice, indicating that exon 11-associated 6TM variants mediate IBNtxA analgesic action.
The most significant finding in the 2011 study was that despite its potent pain-relieving action, IBNtxA lacked the traditional opiate side effects, such as respiratory depression, reward behaviour, significant constipation and physical dependence. To further confirm the role of the 6TM variants in IBNtxA analgesic action, Dr Pan and his team used a gain-of-function approach to see if IBNtxA analgesia can be regained by re-expressing the 6TM variants in a complete Oprm1 knockout mouse, in which all the analgesic actions of mu opioids and IBNtxA were lost. They found that IBNtxA but not morphine analgesia was rescued by the lentivirus expressing the 6TM variants in a complete Oprm1 knockout mouse and published the finding in 2015 in the Journal of Clinical Investigation and 2018 in Anesthesiology & Analgesia.
Together, these studies demonstrated that truncated 6TM variants can be physiologically and pharmacologically important and act as new therapeutic targets for a novel class of opiate compounds displaying a vastly improved pharmacological profile.
Targeting Specific Carboxylic End of the OPRM1 7TM Variants
While the relevance of the truncated variants has been extensively explored and validated by Dr Pan and others, as described in the examples above, they examined the pharmacological roles of the full-length 7TM variants. Alternative splicing of the mu opioid receptor gene OPRM1 creates multiple full-length 7TM mu receptor variants or isoforms, which only differ in the intracellular carboxylic terminal (C-terminal) portion of the receptor. Many in vitro cell line studies conducted by Dr Pan’s laboratory and others indicated that although these full-length 7TM C-terminal variants bound mu opioids equally well because they shared the same binding pocket, they showed marked differences in mu agonist-induced cellular responses.
However, the main question remained regarding their in vivo roles in mu opioid actions, which led Dr Pan and his team to generate several C-terminal truncation mouse models to investigate the in vivo action of mu opioids. They created three mouse models with truncation of either all the C-termini (mE3M mice), or exon 4-encoded C-termini (mE4M) or exon 7-encoded C-termini (mE7M), and observed divergent roles for the carboxylic termini in morphine-induced behaviours in these mouse models, highlighting the importance of C-terminal variants in the modulation of complex morphine actions.
The results of the investigation, published in 2017 in the Journal of Clinical Investigation, showed that the exon 7 truncation in mE7M-B6 mice diminished morphine tolerance and reward without altering physical dependence, whereas the exon 4 truncation in mE4M-B6 mice facilitated morphine tolerance and reduced morphine dependence with no effect on morphine reward.
It is important to understand that dependence on a drug is different from drug tolerance. The latter occurs when the body needs a higher dose of the same drug to reach the same level of perceived benefits. Dependence, on the other hand, happens when the body experiences a loss of function in the absence of a drug, which can manifest itself as a series of painful withdrawal symptoms. Although tolerance and dependence often go hand-in-hand, they can happen through different biochemical mechanisms, as Dr Pan and his collaborators showed in a 2017 paper.
This paper represented a major advance in the understanding of the functional relevance of mu opioid receptor C-terminal splice variants in mu opioid pharmacology, with several important therapeutic implications. First, the researchers demonstrated that different sequences of the carboxylic terminus can alter drug-induced side effects without affecting the pain-relieving properties of opioids. Second, they showed that targeting specific carboxylic terminus of the mu opioid receptors could be an effective therapeutic strategy in the pursuit of novel drugs with more desirable pharmacological profiles and decreased side effects. Also, it is conceivable that opioid therapies targeting exon 7-associated mu receptor splice variants could decrease the addictive effects of opioids, with important implications for the opioid abuse that affects many countries.
Biased Signalling of Mu Opioids at Multiple OPRM1 Carboxylic Terminal Variants
The concept of biased signalling can be explained by looking at the large body of evidence in the medical literature showing that different agonists can trigger divergent signalling pathways through a single receptor. The co-existence of multiple OPRM1 full-length carboxyl terminal variants raises important questions about the role of these variants on the biased signalling through a single mu agonist.
In the same 2017 paper and a later 2020 paper, Dr Pan and his team demonstrated that a single mu agonist can induce biased signalling through multiple 7TM carboxyl terminal variants in terms of G protein activation and β-arrestin 2 recruitment, providing a new perspective on biased signalling.
In particular, exon 7-associated 7TM variant, mMOR-1O, displayed greater β-arrestin 2 bias for most mu agonists than exon 4-associated 7TM variant, mMOR-1, which explained, at least in part, why similar morphine actions existed between mE7M-B6 and β-arrestin 2 knockout mice. These studies opened up a new interesting research avenue for the exploration of the roles of other carboxyl-terminal sequences in biased signalling, as there are 22 full-length carboxyl-terminal variants in the mouse OPRM1 gene, 12 in the rat OPRM1 gene and 11 in the human OPRM1 gene that we know of.
Dr Pan and his team will continue to investigate the mechanisms and functions of different mu opioid receptor variants in the action of opioids using several cutting-edge technologies. The proposed studies include mapping mu agonist‑induced receptor‑protein interactions for OPRM1 splice variants using proximity biotinylation coupled with proteomics, defining molecular mechanisms of morphine actions using phosphoproteomics and RNA sequencing approaches, and exploring molecular mechanisms and functions of OPRM1 alternative splicing using mini-gene constructs and high-throughput siRNA screening. They believe that these studies will provide potential targets for developing novel therapeutics for the treatment of pain and drug abuse.
The team led by Dr Pan will further examine the in vivo role played by individual OPRM1 splice variants in the pharmacological action of mu opioids by using new genetically engineered animal models. These studies will allow the researchers to link each receptor with a particular function. Dr Pan is also aiming to improve the overall pharmacological profiles of opioids by using novel targeting strategies. Evidence in the medical literature suggests that up to 80% of addicts started with prescription drugs. Efforts to find substitutes for opioid drugs would help address the opiate abuse crisis.
Finally, Dr Pan is a co-scientific founder of Sparian Bioscience. One of the most promising drugs at Sparian Bioscience, SBS-1000, is the second generation of IBNtxA that is more potent than morphine but without the many side effects associated with traditional opiates. This compound is expected to be in a Clinical Phase I Trial in early 2022.
MEET THE RESEARCHER
Dr Ying-Xian Pan
Department of Anesthesiology
Rutgers New Jersey Medical School
Brain Health Institute, Rutgers University
Dr Ying-Xian Pan obtained his MD in 1982 from the Shanghai University of Traditional Chinese Medicine, China. In 1986, he obtained his MS Degree in Biochemistry from the Shanghai University of Traditional Chinese Medicine and then moved to the USA, where he obtained his PhD in Physiology and Biophysics in 1993 from the University of Cincinnati, Ohio. Dr Pan continued his research career as an Aaron Diamond Foundation Postdoctoral Fellow at the Memorial Sloan-Kettering Cancer Center, New York, where he met his mentor Dr Gavril W. Pasternak, a renowned pharmacologist. After completing his postdoctoral fellowship, he joined the Department of Neurology in 1999, where he became a full member of the faculty in 2013. Dr Pan is currently Professor of Anaesthesiology at the Rutgers New Jersey Medical School and a core member at the Rutgers Brain Health Institute. Through studying the mechanisms of opioid actions, Dr Pan aims to develop novel strategies and drugs for treating pain and combating the opioid epidemic. Dr Pan is a co-scientific founder of Sparian Biosciences, a company devoted to the development of safer alternatives to opiate drugs.
Dr Gavril Pasternak (passed away on 2/22/2019), Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Dr Susruta Majumdar, Washington University School of Medicine, St. Louis, MO, USA
Dr Grace Rossi, Long Island University, NY, USA
Dr Channabasavaiah Gurumurthy, University of Nebraska, Omaha, NE, USA
Dr John Pintar, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA
National Institute on Drug Abuse, National Institutes of Health
The Mayday Foundation
The Peter F. McManus Trust
Aaron Diamond Foundation
Memorial Sloan-Kettering Cancer Center
Brain Health Institute, Rutgers University
Rutgers New Jersey Medical School
A Narayan, A Hunkele, DL Bassoni, et al., Mu opioid induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, Oprm1, Cell Molecular Neurobiology, 2020, 41, 1059–1074.
J Xu, ZG Lu, A Narayan, et al., Alternatively spliced C-termini of mu opioid receptors impact morphine action, Journal of Clinical Investigation, 2017, 127, 1561–1573.
GW Pasternak, S Childers, XY Pan, Emerging Insights into mu opioid pharmacology. Chapter 5, In Substance Use Disorders: From Etiology to Treatment (Nader MA and Hurd Y, Eds), Springer, 2019.
GW Pasternak, YX Pan, Mu opioids and their receptors: Evolution of a concept, Pharmacological Reviews, 2013, 65, 1–61.
S Majumdar, S Grinnell, V Le Rouzic, et al., Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects, Proceedings of the National Academy of Science, 2011, 108, 19778–19783.
YX Pan, J Xu, M Xu, et al., Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions, Proceedings of the National Academy of Science, 2009, 106, 4917–4921.
REPUBLISH OUR ARTICLES
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence (CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License.
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
MORE ARTICLES YOU MAY LIKE
Dr Arpan Ashok Patel of the University of Rochester School of Medicine and Dentistry is dedicated to better understanding the prevalence and impact of financial toxicity amongst older, more advanced cancer patients. His recent work in this field is the first to analyse real conversations between patients and oncologists in this high-risk group. His findings show that those struggling with financial stability following cancer treatment are more likely to have a lower health-related quality of life, highlighting the need for better screening tools to identify at-risk patients to allow appropriate signposting to support.
As fundamental components of our electronic and optical devices, semiconductors are essential to our modern way of life. Dr Yasuo Koide of the National Institute for Material Science in Japan has an extensive history of researching and developing these unique materials. Alongside his colleagues, Dr Koide continues to break through the boundaries of our existing knowledge to create new and exciting technologies.
To manage their farms effectively, dairy farmers must base their decisions on real-time and continuous data streams, which collect information about feeding, milking, and an array of other factors. Dairy Brain is a toolkit introduced by Dr Victor E. Cabrera and his colleagues at the University of Wisconsin – Madison, which integrates the data streams collected by different software onto a single platform, and applies the latest algorithms to reveal novel insights. The technology could soon enable farmers and industry professionals to make far better use of the latest techniques in data analysis – and may even lead to new advances in efficiency and sustainability.
Rabies is transmitted from animals to humans through the bite of an infected animal, all too often with fatal consequences, particularly in the developing world. Dr Joanne Maki, Technical Director for the Veterinary Public Health Centre at Boehringer-Ingelheim Animal Health, has worked in rabies prevention for 30 years. With extensive background and experience gained in the rabies vaccine industry, Dr Maki shares her perspectives on the call to action to eliminate this deadly zoonotic disease.